{'fraction_non_alphanumeric': 0.02588235294117647, 'fraction_numerical': 0.023529411764705882, 'mean_word_length': 4.828767123287672, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Changes in Blood Glucose Levels and Body Weight in Patients Administered Sodium-Glucose Cotransporter 2 Inhibitors

A few patients who are administered sodium-glucose co-transporter 2 inhibitors (SGLT2i) for the first time often show an increase in their body weight and/or blood glucose levels. In this study, we used an electronic medical record database to identify the factors that affect blood glucose levels and body weight after the administration of SGLT2i. We investigated 1,663 patients who had been prescribed SGLT2i for the first time in a Korean hospital between December 2014 and December 2016. Based on the HbA1c levels measured 3 months following administration of SGLT2i, we observed that the blood glucose levels were significantly lowered in women or in elderly patients (all p Disclosure H. Kim: None. E. Lee: None. K. Yoon: None.